Diagnosis and therapy of cancer (i.e. leukemia and prostate) tailored for the patient subgroup re-sistant to TRAIL induced apopt
TRAIL has recently emerged as a novel potential anticancer agent. However, cancer cells are in specific patients resistant to TRAIL induced apoptosis. Therefore the efficacy of chemotherapy for treatment of CLL, MCL, HNSCC, bladder or prostate carci-noma is often limited due to resistance to TRAIL induced apoptosis. The technology provides a method for identification of these non-responders. Moreover, a polynucleotide encoding the modified TRAIL can serve as drug against such cancer diseases of this specific patient subgroup.
Further Information: PDF
Deutsches Krebsforschungszentrum DKfZ
Phone: +49-6221-422958
Contact
Regina Otto
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Peptides on Interstellar Ice
A research team led by Dr Serge Krasnokutski from the Astrophysics Laboratory at the Max Planck Institute for Astronomy at the University of Jena had already demonstrated that simple peptides…
A new look at the consequences of light pollution
GAME 2024 begins its experiments in eight countries. Can artificial light at night harm marine algae and impair their important functions for coastal ecosystems? This year’s project of the training…
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
